WO2015191911A3 - Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation - Google Patents

Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation Download PDF

Info

Publication number
WO2015191911A3
WO2015191911A3 PCT/US2015/035413 US2015035413W WO2015191911A3 WO 2015191911 A3 WO2015191911 A3 WO 2015191911A3 US 2015035413 W US2015035413 W US 2015035413W WO 2015191911 A3 WO2015191911 A3 WO 2015191911A3
Authority
WO
WIPO (PCT)
Prior art keywords
making
methods
same
protein
protein enriched
Prior art date
Application number
PCT/US2015/035413
Other languages
English (en)
Other versions
WO2015191911A2 (fr
Inventor
Michael Haugwitz
Thomas Patrick Quinn
Montserrat Morrell
Andrew Alan Farmer
Original Assignee
Clontech Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clontech Laboratories, Inc. filed Critical Clontech Laboratories, Inc.
Publication of WO2015191911A2 publication Critical patent/WO2015191911A2/fr
Publication of WO2015191911A3 publication Critical patent/WO2015191911A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une microvésicule comprenant les éléments suivants : (i) une protéine associée à une membrane comportant au moins un premier domaine de dimérisation ; (ii) une protéine porteuse comprenant au moins un second domaine de dimérisation ; et (iii) un soluté qui se lie à la protéine porteuse, ledit soluté étant choisi dans le groupe constitué de l'ADN, l'ARN, les protéines, les glucides, les ribosomes, les mitochondries, et les petites molécules. La présente invention concerne en outre des cellules, des réactifs et des kits utiles dans la fabrication des microvésicules, ainsi que des procédés d'utilisation desdites microvésicules, par exemple, dans la recherche et pour des applications thérapeutiques.
PCT/US2015/035413 2014-06-12 2015-06-11 Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation WO2015191911A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011528P 2014-06-12 2014-06-12
US62/011,528 2014-06-12

Publications (2)

Publication Number Publication Date
WO2015191911A2 WO2015191911A2 (fr) 2015-12-17
WO2015191911A3 true WO2015191911A3 (fr) 2016-03-31

Family

ID=54834565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/035413 WO2015191911A2 (fr) 2014-06-12 2015-06-11 Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation

Country Status (1)

Country Link
WO (1) WO2015191911A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (fr) 2011-07-22 2019-09-04 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
JP7067793B2 (ja) 2015-10-23 2022-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基編集因子およびその使用
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11866699B2 (en) 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (fr) 2017-03-10 2020-01-15 President and Fellows of Harvard College Éditeur de base cytosine à guanine
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
WO2019079347A1 (fr) 2017-10-16 2019-04-25 The Broad Institute, Inc. Utilisations d'éditeurs de bases adénosine
JP2021524272A (ja) * 2018-07-10 2021-09-13 エーエルアイエー セラピューティクス エス． アール． エル． ガイドｒｎａ分子および／またはガイドｒｎａ分子／ｒｎａ誘導型ヌクレアーゼ複合体の無痕跡送達のための小胞およびその産生方法
EP3942040A1 (fr) 2019-03-19 2022-01-26 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
WO2021226558A1 (fr) 2020-05-08 2021-11-11 The Broad Institute, Inc. Méthodes et compositions d'édition simultanée des deux brins d'une séquence nucléotidique double brin cible

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058064A1 (fr) * 2009-11-13 2011-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Reprogrammation de cellules eucaryotes par des microvésicules obtenues par génie génétique
US20130323220A1 (en) * 2012-05-29 2013-12-05 The General Hospital Corporation TAL-Tet1 Fusion Proteins and Methods of Use Thereof
WO2013188522A2 (fr) * 2012-06-12 2013-12-19 Genentech, Inc. Procédés et compositions pour la génération d'allèles à inactivation conditionnelle
WO2014036391A1 (fr) * 2012-08-30 2014-03-06 Exosome Diagnostics, Inc. Témoins pour dosages d'acide nucléique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058064A1 (fr) * 2009-11-13 2011-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Reprogrammation de cellules eucaryotes par des microvésicules obtenues par génie génétique
US20130323220A1 (en) * 2012-05-29 2013-12-05 The General Hospital Corporation TAL-Tet1 Fusion Proteins and Methods of Use Thereof
WO2013188522A2 (fr) * 2012-06-12 2013-12-19 Genentech, Inc. Procédés et compositions pour la génération d'allèles à inactivation conditionnelle
WO2014036391A1 (fr) * 2012-08-30 2014-03-06 Exosome Diagnostics, Inc. Témoins pour dosages d'acide nucléique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIMIN LI ET AL.: "Argonaute 2 Complexes Selectively Protect the Circulating MicroRNAs in Cell -Secreted Microvesicles", PLOS ONE, vol. 7, no. 10, 2012, pages 1 - 9 *

Also Published As

Publication number Publication date
WO2015191911A2 (fr) 2015-12-17

Similar Documents

Publication Publication Date Title
WO2015191911A3 (fr) Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
AR118722A2 (es) Proteínas tóxicas para especies de insectos hemípteros
WO2015089511A3 (fr) Molécules d'acides nucléiques modifiés et leurs utilisations
WO2015196128A3 (fr) Molécules d'acide nucléique alternatives et leurs utilisations
WO2015196130A3 (fr) Molécules d'acide nucléique alternatives et leurs utilisations
EP4303314A3 (fr) Nucléotides à marquage polypeptidique et leur utilisation dans le séquençage d'acide nucléique par détection par nanopores
WO2017178653A3 (fr) Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques
WO2015188839A3 (fr) Détection générale et isolement de cellules spécifiques par liaison de molécules marquées
WO2015028969A3 (fr) Tampon de transduction
NZ741129A (en) Anti-pd1 antibodies and methods of use
MX2021002826A (es) Nuevo formato biespecifico adecuado para uso en tamizado de alto rendimiento.
WO2017024317A3 (fr) Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
WO2016100261A3 (fr) Procédé de traitement du cancer avec cgamp ou cgasmp
EA201890315A1 (ru) Молекулы антител, связывающие cd22
BR112017003582A2 (pt) anticorpos, composições e usos
WO2016061389A3 (fr) Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
MX2021010668A (es) Proteinas de fusion de citoquinas.
WO2014074648A3 (fr) Compositions de riborégulateur et procédés d'utilisation
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
WO2015195453A3 (fr) Procédés pour augmenter la capacité de processus à écoulement continu
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
WO2015058132A3 (fr) Anticorps anti-rspo et leurs méthodes d'utilisation
WO2018126278A3 (fr) Procédés de distinction d'arn et d'adn dans une préparation combinée
WO2015077657A3 (fr) Inhibiteurs de stat3 et leurs utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15807095

Country of ref document: EP

Kind code of ref document: A2